Clinical Trial Update: A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update for IMC-3C5, an anti-VEGFR-3 monoclonal antibody, in subjects with advanced solid tumors; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• IMC-3C5

Snippet

Sponsor: Eli Lilly and Company | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2019-06-17